Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006884 · ClinicalTrials.gov registry record
A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
A clinical trial of COVID-19, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT06006884: Recruiting study of COVID-19, sponsored by Mayo Clinic.
NCT06006884 is a study of COVID-19 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 75 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06006884, a study of COVID-19, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection
Primary Outcome
This study will expand on prior observations from a previous study and discover potential drivers and targets for therapy of post-acute COVID-19 lung disease by recruiting a larger group of COVID-19 convalescents, following up longitudinally up to 12 months after acute infection. This longitudinal approach will allow for assess immune dysregulation and establish the etiology of lung sequelae of COVID-19
Conditions Studied
Interventions
- PROCEDURE Bronchoscopies and Bronchoalveolar Lavages (BALs)
- DIAGNOSTIC_TEST Chest Tomography (CT)
- DIAGNOSTIC_TEST Electrocardiogram (ECG)
- DIAGNOSTIC_TEST Pulmonary function tests (PFTs)
- DIAGNOSTIC_TEST 6 minute walk test (6MWT)
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2027-08 |
What NCT06006884 shows while recruiting
NCT06006884 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Bronchoscopies and Bronchoalveolar Lavages (BALs) is the first listed.
NCT06006884 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06006884 about?
NCT06006884 is a clinical study titled "A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae". The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection
What is the current status of trial NCT06006884?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2024-01-10. Estimated completion is 2027-08.
What conditions does trial NCT06006884 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06006884?
The interventions under investigation include: Bronchoscopies and Bronchoalveolar Lavages (BALs) (PROCEDURE), Chest Tomography (CT) (DIAGNOSTIC_TEST), Electrocardiogram (ECG) (DIAGNOSTIC_TEST), Pulmonary function tests (PFTs) (DIAGNOSTIC_TEST), 6 minute walk test (6MWT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06006884?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006884 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06006884's enrollment target sits among peer trials
75 225th of 298 higher than 74 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI